* Enfusion Inc ENFN.N ENFN.K is expected to show a rise
in
quarterly revenue when it reports results on March 12 for the
period ending December 31 2023
* The Chicago Illinois-based company is expected to report
a
11.7% increase in revenue to $45.275 million from $40.52 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Enfusion Inc is for
earnings
of 5 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Enfusion
Inc is
$9.88, above its last closing price of $8.33.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 0.04 0.05 0.04 Missed -12.5
Jun. 30 2023 0.04 0.04 0.04 Met -4.1
Mar. 31 2023 0.03 0.03 0.02 Missed -27.1
Dec. 31 2022 0.03 0.03 0.04 Beat 36.4
Sep. 0.01 0.02 0.03 Beat 50
30 2022
Jun. 30 2022 0.02 0.02 0.04 Beat 100
Mar. 31 2022 0.03 0.03 0.00 Missed -93.6
Dec. 31 2021 0.03 0.04 0.02 Missed -43.6
This summary was machine generated March 8 at 13:17 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)